

AMENDMENT

In response to the office action dated July 25, 1995,
please amend the above-identified application as follows:

IN THE SPECIFICATION:

Please amend the specification as follows:

On page 1, line 5, please cancel "METHOD" and
substitute therefor --THE USE OF ANTIBODIES SPECIFIC TO
HUMAN COMPLEMENT COMPONENT C5 --.

Similarly, please amend the title of the application as
contained in the records of the Patent and Trademark Office
to read:

--THE USE OF ANTIBODIES SPECIFIC TO HUMAN COMPLEMENT
COMPONENT C5 FOR THE TREATMENT OF GLOMERULONEPHRITIS --.

IN THE CLAIMS:

Please cancel, without prejudice, claims 6-9, and amend
Claim 1 as follows:

cat
C'
--1. (amended) A method for the treatment of
glomerulonephritis in a patient in need of such treatment
comprising introducing an antibody [that binds] specific to
complement component C5 into the patient's bloodstream in an
amount effective to substantially reduce the cell-lysing
ability of complement present in the patient's blood.

FILE COPY